Biologics update: IL‐23 inhibitors. Issue 5 (27th October 2021)

• Record Type: Journal Article
• Authors: Hong, Julie; Hadeler, Edward; Mosca, Megan; Chung, Mimi; Yeroushalmi, Samuel; Hakimi, Marwa; Liao, Wilson; Bhutani, Tina
• Other Names: Wu Jashin J. guestEditor.
• Is Part Of: Dermatological reviews. Volume 2:Issue 5(2021)
• Page Start: 276
• Page End: 281
• Publication Date: 2021-10-27
• Subjects: guselkumab -- IL‐23 -- psoriasis -- risankizumab -- tildrakizumab; Dermatology -- Periodicals; Electronic journals; 616.5
• DOI: 10.1002/der2.97
• Languages: English
• ISSNs: 2637-7489

Abstract

Abstract: Introduction: IL‐23 inhibitors have shown long‐term efficacy and safety for the treatment of moderate‐to‐severe plaque psoriasis in adults. Guselkumab has also been approved to treat psoriatic arthritis while tildrakizumab and risankizumab are currently under investigation for treating psoriatic arthritis. The goal of this paper is to review and highlight the most current benefits and potential adverse events of IL‐23 inhibitors for psoriasis treatment. Methods: A literature search was performed using the MEDLINE (PubMed), Embase, PsycINFO, and Web of Science databases. Only Phase III and Phase IV clinical studies were reviewed for the purpose of this paper. Results: Clinical studies have shown IL‐23 inhibitors demonstrate superior efficacy compared to IL‐12/23 inhibitors and TNF‐a inhibitors. Adverse events with IL‐23 inhibitors are minimal, and the most common side effect is increased risk of infection. Conclusion: Tildrakizumab, risankizumab, and guselkumab are IL‐23 inhibitors that are approved for the treatment of moderate‐to‐severe psoriasis. Multiple head‐to‐head trials have demonstrated long‐term efficacy and safety of IL‐23 inhibitors, compared to IL‐17 inhibitors, which have demonstrated short‐term efficacy.